8 July 2025NewsFuture of IPHa Kung Wong, Venable | Karen Martin, Ipsen | Nitin Virmalwar, Stoke Therapeutics | Jennifer Moitoso, Biogen
WATCH: Mastering the art of IP transactions—due diligence, valuation, and deal-making
LSPN brings together experts from Venable, Ipsen, Stoke Therapeutics, and Biogen to analyse best practices for IP transactions, from due diligence and valuation to structuring deals.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
5 August 2025 A much-anticipated referral could upend the EPO’s controversial description amendment rule—and reshape European patent practice, as the Enlarged Board of Appeal prepares to weigh in on G 1/25. Marisa Woutersen reports.